These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22472064)

  • 1. Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.
    Jensen AD; Krauss J; Potthoff K; Simon C; Nikoghosyan AV; Lossner K; Debus J; Münter MW
    Radiat Oncol; 2012 Apr; 7():57. PubMed ID: 22472064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
    Habl G; Jensen AD; Potthoff K; Uhl M; Hof H; Hajda J; Simon C; Debus J; Krempien R; Münter MW
    BMC Cancer; 2010 Nov; 10():651. PubMed ID: 21108850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
    Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
    Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
    Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
    Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.
    Alongi F; Bignardi M; Garassino I; Pentimalli S; Cavina R; Mancosu P; Reggiori G; Poletti A; Ferrari D; Foa P; Bigoni A; Dragonetti A; Salvatori P; Spahiu O; Fogliata A; Cozzi L; Santoro A; Scorsetti M
    Strahlenther Onkol; 2012 Jan; 188(1):49-55. PubMed ID: 22194030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).
    Tao Y; Aupérin A; Sun X; Sire C; Martin L; Coutte A; Lafond C; Miroir J; Liem X; Rolland F; Even C; Nguyen F; Saada E; Maillard A; Colin-Batailhou N; Thariat J; Guigay J; Bourhis J
    Eur J Cancer; 2020 Dec; 141():21-29. PubMed ID: 33125944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck.
    Matuschek C; Bölke E; Belka C; Ganswindt U; Henke M; Stegmaier P; Bamberg M; Welz S; Debus J; Gioules A; Voigt A; Volk G; Ohmann C; Wiegel T; Budach V; Stuschke M; Schipper J; Gerber PA; Budach W
    Strahlenther Onkol; 2013 Aug; 189(8):625-31. PubMed ID: 23824104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
    Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
    Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT.
    Jensen AD; Krauss J; Potthoff K; Desta A; Habl G; Mavtratzas A; Windemuth-Kiesselbach C; Debus J; Münter MW
    BMC Cancer; 2011 May; 11():182. PubMed ID: 21595970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer.
    Huang J; Baschnagel AM; Chen P; Gustafson G; Jaiyesmi I; Folbe M; Ye H; Akervall J; Krauss D
    Int J Clin Oncol; 2014 Apr; 19(2):240-6. PubMed ID: 23479120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).
    Shapiro LQ; Sherman EJ; Riaz N; Setton J; Koutcher L; Zhang Z; Shi W; Fury MG; Wolden SL; Pfister DG; Morris L; Lee N
    Oral Oncol; 2014 Oct; 50(10):947-55. PubMed ID: 25132089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
    Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
    Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
    Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
    Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.
    Habl G; Potthoff K; Haefner MF; Abdollahi A; Hassel JC; Boller E; Indorf M; Debus J
    BMC Cancer; 2013 Jul; 13():345. PubMed ID: 23855804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Jensen AD; Krauss J; Weichert W; Bergmann ZP; Freier K; Debus J; Münter MW
    Radiat Oncol; 2011 Sep; 6():122. PubMed ID: 21942981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
    Tinhofer I; Hristozova T; Stromberger C; Keilhoiz U; Budach V
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e685-90. PubMed ID: 22583603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results.
    Balermpas P; Keller C; Hambek M; Wagenblast J; Seitz O; Rödel C; Weiss C
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e377-83. PubMed ID: 22414284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
    Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
    Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.